KR20240007391A - A local cleanser with antibacterial and antifungal ingredients derived from natural products to prevent candidiasis - Google Patents
A local cleanser with antibacterial and antifungal ingredients derived from natural products to prevent candidiasis Download PDFInfo
- Publication number
- KR20240007391A KR20240007391A KR1020220084216A KR20220084216A KR20240007391A KR 20240007391 A KR20240007391 A KR 20240007391A KR 1020220084216 A KR1020220084216 A KR 1020220084216A KR 20220084216 A KR20220084216 A KR 20220084216A KR 20240007391 A KR20240007391 A KR 20240007391A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- cleanser
- derived
- oil
- Prior art date
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 19
- 230000000843 anti-fungal effect Effects 0.000 title claims abstract description 16
- 229930014626 natural product Natural products 0.000 title claims abstract description 16
- 241000222122 Candida albicans Species 0.000 title claims abstract description 14
- 206010007134 Candida infections Diseases 0.000 title claims abstract description 11
- 201000003984 candidiasis Diseases 0.000 title claims abstract description 11
- 239000004615 ingredient Substances 0.000 title claims abstract description 10
- 229940121375 antifungal agent Drugs 0.000 title claims abstract description 9
- 239000000284 extract Substances 0.000 claims abstract description 19
- 102000004190 Enzymes Human genes 0.000 claims abstract description 15
- 108090000790 Enzymes Proteins 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 230000000699 topical effect Effects 0.000 claims abstract description 14
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 12
- 239000004094 surface-active agent Substances 0.000 claims abstract description 11
- 239000008158 vegetable oil Substances 0.000 claims abstract description 11
- 229940043810 zinc pyrithione Drugs 0.000 claims abstract description 9
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000008213 purified water Substances 0.000 claims abstract description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 14
- 239000003921 oil Substances 0.000 claims description 10
- 235000019198 oils Nutrition 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 9
- 235000020694 echinacea extract Nutrition 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 241000018646 Pinus brutia Species 0.000 claims description 6
- 241000191967 Staphylococcus aureus Species 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229940095731 candida albicans Drugs 0.000 claims description 4
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims description 3
- 240000003553 Leptospermum scoparium Species 0.000 claims description 3
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 3
- 235000008524 evening primrose extract Nutrition 0.000 claims description 3
- 239000010475 evening primrose oil Substances 0.000 claims description 3
- 229940089020 evening primrose oil Drugs 0.000 claims description 3
- 239000010460 hemp oil Substances 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 230000009036 growth inhibition Effects 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 206010040880 Skin irritation Diseases 0.000 abstract description 2
- 239000000419 plant extract Substances 0.000 abstract description 2
- 230000001568 sexual effect Effects 0.000 abstract description 2
- 231100000475 skin irritation Toxicity 0.000 abstract description 2
- 230000036556 skin irritation Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 35
- 210000003491 skin Anatomy 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000004140 cleaning Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000002537 cosmetic Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000001965 potato dextrose agar Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 244000133098 Echinacea angustifolia Species 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 230000001877 deodorizing effect Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 235000014134 echinacea Nutrition 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000787 lecithin Substances 0.000 description 5
- 235000010445 lecithin Nutrition 0.000 description 5
- 229940067606 lecithin Drugs 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 235000019645 odor Nutrition 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 239000002038 ethyl acetate fraction Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000001840 Dandruff Diseases 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 240000000759 Lepidium meyenii Species 0.000 description 3
- 235000000421 Lepidium meyenii Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010046914 Vaginal infection Diseases 0.000 description 3
- 201000008100 Vaginitis Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000012902 lepidium meyenii Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 231100000245 skin permeability Toxicity 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000002834 transmittance Methods 0.000 description 3
- 208000010484 vulvovaginitis Diseases 0.000 description 3
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000002768 Kirby-Bauer method Methods 0.000 description 2
- 241000555676 Malassezia Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 244000234609 Portulaca oleracea Species 0.000 description 2
- 235000001855 Portulaca oleracea Nutrition 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000012459 cleaning agent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229940073499 decyl glucoside Drugs 0.000 description 2
- 238000004332 deodorization Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000002044 hexane fraction Substances 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 229940094506 lauryl betaine Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 2
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229940079988 potassium cocoyl glycinate Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 229940079781 sodium cocoyl glutamate Drugs 0.000 description 2
- 229940079776 sodium cocoyl isethionate Drugs 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000435122 Echinopsis terscheckii Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 244000025361 Ficus carica Species 0.000 description 1
- 235000008730 Ficus carica Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 241000029132 Paronychia Species 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010069055 Vulvovaginal pain Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002034 butanolic fraction Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 239000002036 chloroform fraction Substances 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000003670 easy-to-clean Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- -1 immune-enhancing Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 210000000260 male genitalia Anatomy 0.000 description 1
- 239000006994 mh medium Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000010152 pollination Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000003859 smegma Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4933—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having sulfur as an exocyclic substituent, e.g. pyridinethione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 칸디다증을 예방하는 천연물 유래 항균 항진균 성분의 국부 세정제에 관한 것이다. 본 발명의 천연물 유래 국부 세정제는 무화과 효소 추출물 0.1~3 중량부, 징크피리치온 0.05~0.5 중량부, 계면활성제 10~30 중량부, 식물성 오일 5~10 중량부, 산도조절제 0.1~3 중량부 및 나머지 중량부의 정제수를 포함한다. 본 발명은 경피흡수율을 높여 항균 및 항진균 효과를 강화한 비건 남성 청결제를 제공하며, 또한 천연 식물 추출물을 포함하여 피부 자극성을 줄이고 악취를 감소시켜 생식기 위생 상태 개선에 도움을 주고 성생활 만족도를 높이는 효과가 있다.The present invention relates to a topical cleanser containing antibacterial and antifungal ingredients derived from natural products to prevent candidiasis. The natural product-derived topical cleanser of the present invention contains 0.1 to 3 parts by weight of fig enzyme extract, 0.05 to 0.5 parts by weight of zinc pyrithione, 10 to 30 parts by weight of surfactant, 5 to 10 parts by weight of vegetable oil, and 0.1 to 3 parts by weight of acidity regulator. and the remaining parts by weight of purified water. The present invention provides a vegan men's cleanser with enhanced antibacterial and antifungal effects by increasing the transdermal absorption rate, and also contains natural plant extracts to reduce skin irritation and reduce bad odor, which helps improve genital hygiene and increases satisfaction with sexual life. .
Description
본 발명은 천연물 유래 국부 세정제에 관한 것이다. 더욱 상세하게는 항균성, 항진균성을 가지고 소취효과가 탁월한 칸디다증을 예방하는 천연물 유래 항균 항진균 성분의 국부 세정제에 관한 것이다.The present invention relates to topical cleansers derived from natural products. More specifically, it relates to a topical cleanser containing antibacterial and antifungal ingredients derived from natural products that has antibacterial and antifungal properties and has excellent deodorizing effects to prevent candidiasis.
근래에 범세계적인 코로나-19 팬데믹 사태를 겪으면서 위생용품과 청결용품에 대한 관심이 급증하였고, 관련 시장과 매출규모가 급성장하고 있는 중이다.Recently, due to the global COVID-19 pandemic, interest in hygiene products and cleaning products has increased rapidly, and the related market and sales volume are growing rapidly.
여성은 악취가 나기 쉬운 생식기계통 신체구조와, 부인과 질병을 예방하려는 요인에 의해서 여성청결제나 질 세정제와 같은 국부세정용품이 다양하게 출시되어 왔다. 그러한 국부세정용품이 예방하려는 대표적인 질환이 칸디다성 질염이다. 부인과 질병 중 하나인 칸디다성 외음질염은 여성의 75% 정도가 일생에 한 번 이상 경험하며, 여성의 45% 정도는 1년에 2회 이상 경험할 정도로 흔한 질환이다. 항상 신체 분비물의 영향하에 있으며, 표피가 없는 점막구조의 특징상 여성 성기는 세균성, 진균성 질환에 감염되기 쉽다. 여성청결제는 이 점에 주목하여 소독 살균 효과, 세정 효과로 감염성 질환을 예방함은 물론이고, 소취, pH조절, 보습, 비점성, 면역성 강화 등 보조적 기능을 제공하는 바, 많은 연구개발이 이루어져 왔으며 다양한 원료와 기능의 상품이 출시되고 있다.A variety of topical cleansing products, such as feminine cleansers and vaginal cleansers, have been released due to women's reproductive system structure that is prone to bad odors and factors aimed at preventing gynecological diseases. The representative disease that such topical cleaning products are intended to prevent is candidal vaginitis. Candida vulvovaginitis, one of the gynecological diseases, is a common disease that about 75% of women experience at least once in their lives, and about 45% of women experience it at least twice a year. The female genitals are always under the influence of body secretions, and due to the nature of the mucous membrane structure without epidermis, the female genitals are susceptible to bacterial and fungal diseases. Focusing on this point, feminine washes not only prevent infectious diseases through disinfection, sterilization, and cleansing effects, but also provide auxiliary functions such as deodorization, pH control, moisturizing, non-viscosity, and strengthening immunity, and much research and development has been conducted. Products with various raw materials and functions are being released.
그러나 남성의 경우, 상대적으로 세정이 용이한 생식기 구조와, 관심부족으로 인하여 남성청결제의 분야는 그 종류도 많지 않고 그 기능성도 소취효과 및 청량감에 그치는 제한적인 상황이다.However, in the case of men, due to the relatively easy-to-clean genital structure and lack of interest, the field of men's cleansers is limited in that there are not many types and their functionality is limited to a deodorizing effect and a refreshing feeling.
한편으로는, 여성의 전유물로만 여겨지던 화장품 시장이 남성 타겟으로도 점차 확대되어 현재 총 144조원에 달하는 시장규모를 형성하고 있으며, 2026년까지 15.9%의 성장률로 계속 증가할 것으로 예측되고 있다.On the one hand, the cosmetics market, which was considered exclusively for women, has gradually expanded to include male targets, currently forming a total market size of 144 trillion won, and is expected to continue to increase at a growth rate of 15.9% until 2026.
이러한 상황으로 인하여 국내 남성 청결제 시장도 그 규모가 약진하고 있으며 수많은 남성 청결제가 출시되고 있다. 하지만 아직도 소비자들의 구매 필요성을 자극하는 제품은 없기 때문에 보다 다양한 기능성의 제품이 요구되고 있다.Due to this situation, the domestic men's cleanser market is also growing rapidly, and numerous men's cleanser products are being released. However, because there are still no products that stimulate consumers' need to purchase, products with more diverse functionality are required.
대한민국 등록특허 10-1979827호는 남성 청결제 조성물 및 그의 제조방법에 관한 발명이다. 해당 발명은 마카추출물 및 세정제를 주성분으로 하여 살균제, pH조절제, 보습성분 등을 포함하여 에멀젼상을 형성하는 남성 청결제 화장료 조성물의 제조방법을 개시하고 있다.Republic of Korea Patent No. 10-1979827 is an invention relating to a male cleanser composition and its manufacturing method. The invention discloses a method for producing a men's cleanser cosmetic composition that forms an emulsion phase using maca extract and detergent as main ingredients and including a disinfectant, pH adjuster, and moisturizing ingredient.
대한민국 등록특허 10-2385414호는 마카 및 쇠비름 추출물을 유효성분으로 포함하는 남성 청결용 화장료 조성물 및 이의 제조방법에 관한 발명이다. 해당 발명은 마카 및 쇠비름 열수 추출물을 유효성분으로 포함하고 항균 효과 및 미백효과를 가지는 것을 특징으로 한다.Republic of Korea Patent No. 10-2385414 is an invention relating to a cosmetic composition for men's cleanliness containing extracts of maca and purslane as active ingredients and a method of manufacturing the same. The invention contains maca and purslane thermal water extracts as active ingredients and is characterized by having antibacterial and whitening effects.
그러나 기존 발명이나 시중제품을 살펴보아도 기존 남성 청결제는 외피 표면에만 작용할 뿐이고 피부 내측이나 요도에 작용하는 남성 청결제는 전무한 실정이다. 따라서 기존 남성 청결제 제품은 광고하는 바에 비해서 그 성능과 약리적인 면에서 일반 비누와 차이가 없다 할 수 있다.However, even if we look at existing inventions or commercial products, existing male cleansers only act on the outer surface of the skin, and there are no male cleansers that act on the inner skin or urethra. Therefore, compared to what is advertised, existing male cleanser products are no different from regular soap in terms of performance and pharmacology.
전술한 문제점을 해결하기 위한 본 발명의 일 목적은 경피흡수율을 높여 남성기 내부 및 요도에 침투가능하여 항균 및 항진균 효과가 강화된 국부 세정제 제공하는데 있다.One purpose of the present invention to solve the above-mentioned problems is to provide a topical cleanser with enhanced antibacterial and antifungal effects by increasing the transdermal absorption rate so that it can penetrate the inside of the male genitalia and the urethra.
또한 본 발명의 일 목적은 악취의 제거효과가 탁월한 국부 세정를 제공하는 데 있다.Another object of the present invention is to provide a local cleanser with excellent odor removal effect.
또한 본 발명의 일 목적은 식물성 원료를 사용하여 만든 천연물 유래 국부 세정제를 제공하는 데 있다.Another object of the present invention is to provide a natural product-derived topical cleanser made using vegetable raw materials.
전술한 목적을 해결하기 위하여 본 발명은 무화과 칸디다증을 예방하는 천연물 유래 항균 항진균 성분의 국부 세정제를 제공한다.In order to solve the above-mentioned object, the present invention provides a topical cleanser containing antibacterial and antifungal ingredients derived from natural products to prevent fig candidiasis.
구체적으로 본 발명은 무화과 효소 추출물 0.1~3 중량부, 에키네시아 추출물 0.1~2 중량부, 징크피리치온 0.05~0.5 중량부, 소듐폴리나프탈렌설포네이트 0.5~5 중량부를 유효 성분으로 하고, 계면활성제 10~30 중량부, 식물성 오일 5~10 중량부, 산도조절제 0.1~3 중량부 및 나머지 중량부의 정제수를 포함하는, 칸디다증을 예방하는 천연물 유래 항균 항진균 성분의 국부 세정제를 제공한다.Specifically, the present invention contains 0.1 to 3 parts by weight of fig enzyme extract, 0.1 to 2 parts by weight of Echinacea extract, 0.05 to 0.5 parts by weight of zinc pyrithione, and 0.5 to 5 parts by weight of sodium polynaphthalenesulfonate as active ingredients, and a surfactant. Provided is a local cleanser containing antibacterial and antifungal ingredients derived from natural products to prevent candidiasis, comprising 10 to 30 parts by weight, 5 to 10 parts by weight of vegetable oil, 0.1 to 3 parts by weight of an acidity regulator, and the remaining parts by weight of purified water.
상기 무화과(Ficus carica)는 무화과나무속의 식물로 소아시아가 원산지이며 이집트에서 약 4,000년 전에 심은 기록이 있어 세계에서 가장 오래된 과수로 알려져 있다. 무화과는 꽃의 종류, 수분의 필요 유무에 따라 원예적으로 카프리계, 스미르나계, 보통계, 산페드로계의 4종으로 분류되며 이 분화의 과정은 이미 기원전(BC 4~AD 37)부터 오늘날 재배되고 있는 우량품종들이 유럽에서는 이미 재배되고 있었던 것으로 알려지고 있다. 무화과나무 잎은 어긋나고 넓은 달걀 모양이다. 봄부터 여름에 걸쳐 잎겨드랑이에 주머니 같은 꽃차례가 발달하며 그 속에 작은 꽃이 많이 달리는데, 수꽃은 위쪽에 암꽃은 아래쪽에 위치하여 잘 보이지 않는다. 열매는 어두운 자주색의 은화과(隱花果)로 가을에 익으며 식용으로 사용하고 잎은 단백질, 고무질 따위를 함유하여 그 유즙(乳汁)으로 회충 따위의 구제약이나 신경통의 약재로 쓴다. 무화과는 옛날부터 민간 의료약으로서 성경이나 동의보감에서도 아주 소중히 여겨왔다. 효용은 혈압강화, 건위, 자양, 변비, 간장염, 암, 부인병, 활력회복 등에 좋다고 기록되어 있다. 본초강목(명)에 "골장의 작용을 원할하게 하여 주고 설사를 멈추고 인후통을 낫게 한다"고 그 효능이 기재되어 있다. 진남본초(명)에 "일명 명목과라고 하여 오서에는 과피의 유즙으로 자주 씻어주면 좋으며, 맛은 인후를 유화하게 해 줘서 뇌흉을 열고, 간에 들어가서 혈맥의 흐름을 좋게 하고 눈을 맑게 해준다"고 그 효능이 기재되어 있다. 일반적인 효능은 위장약으로서의 작용, 설사나 치질의 치료, 지인후통, 소염작용, 소중작용, 소화촉진 등이 있으며, 그밖에 구충약과 황달에 쓰인다. 동물의 실험으로는 미성열의 과일에서 함유되어 있는 유즙은 유암이나 백혈병, 임퍼육종에 유효했다는 보고가 있다. 무화과는 병충해에 강하며 어린 새순도 깨끗하게 자라며, 농약을 하지 않고 공해 없는 자연속에서 자라는 자연건강식품이다.The fig ( Ficus carica ) is a plant of the fig tree and is native to Asia Minor. There is a record of it being planted in Egypt about 4,000 years ago, making it known as the oldest fruit tree in the world. Figs are horticulturally classified into four species, Capri, Smyrna, Common, and San Pedro, depending on the type of flower and the need for pollination. This differentiation process has already been in cultivation since BC (4 BC - AD 37) and is still cultivated today. It is known that the superior varieties that are being developed are already being cultivated in Europe. Fig tree leaves are alternate and broadly egg-shaped. From spring to summer, sac-like inflorescences develop in the leaf axils, and many small flowers grow inside them. The male flowers are located at the top and the female flowers are located at the bottom, making them difficult to see. The fruit is a dark purple fruit that ripens in the fall and is used as food. The leaves contain protein and rubber, and the juice is used as a remedy for roundworms and neuralgia. Figs have been a folk medicine since ancient times and have been highly prized in the Bible and Donguibogam. It is said to be good for strengthening blood pressure, health, nourishment, constipation, hepatitis, cancer, gynecological diseases, and restoring vitality. In the herbal medicine, its efficacy is described as "promotes smooth functioning of the bone intestine, stops diarrhea, and relieves sore throat." Jinnamboncho (myeong) says, “It is also called Myeongmokgwa, so it is good to wash it frequently with the milky juice of the fruit skin. The taste emulsifies the throat, opens the encephalothorax, and enters the liver to improve the flow of blood vessels and clear the eyes.” Efficacy is described. General effects include acting as a gastrointestinal medicine, treating diarrhea or hemorrhoids, sore throat, anti-inflammatory effect, small intestine effect, promoting digestion, etc. In addition, it is used for anthelmintic medicine and jaundice. In animal experiments, it was reported that the milk contained in the fruit of immature fever was effective in treating breast cancer, leukemia, and Imper's sarcoma. Figs are resistant to pests and diseases, their young shoots grow cleanly, and they are a natural health food that grows in nature without pesticides and without pollution.
상기 무화과의 과육, 잎, 수액 추출물은 항균 및 항진균 효과를 가짐이 여러 연구에서 보고되어 있다. Khaleel Ibrahim Rashid, 2014., Amirah Nadiah Ali, 2018., Shahzada Nadeem Abbas, 2019. 등의 보고에 따르면 무화과 추출물은 여러 박테리아 및 균류에 대해서 강력한 항균 및 항진균 효과를 보임이 확인되었다. 본 발명은 이러한 무화과의 항균 및 항진균 효과에 주목하여 천연물 유래 국부 세정제를 발명하기에 이르렀다.Several studies have reported that the pulp, leaves, and sap extracts of the fig have antibacterial and antifungal effects. According to reports such as Khaleel Ibrahim Rashid, 2014., Amirah Nadiah Ali, 2018., and Shahzada Nadeem Abbas, 2019., it was confirmed that fig extract shows strong antibacterial and antifungal effects against various bacteria and fungi. The present invention focused on the antibacterial and antifungal effects of figs and developed a local cleanser derived from natural products.
본 발명의 무화과 효소 추출물은 무화과 열매를 열수 및 유기용매 추출하여 얻어질 수 있다. 구체적으로 무화과 열매를 채취하여 분쇄한 후, 1~50배 분량의 용매를 가하여 상온에서 12시간~3개월동안 침적법, 압착법 또는 분쇄법으로 추출할 수 있다. 추출 용매는 정제수, 탄소수 1 내지 4의 저급 알코올, 다이클로로메테인, 클로로포름 및 에틸 아세테이트로 이루어지는 군에서 선택되는 어느 하나 이상의 용매를 사용하여 분획 추출할 수 있다. 바람직하게는 메탄올, 에탄올 또는 에틸 아세테이트를 용매로 이용하여 분획 추출할 수 있다.The fig enzyme extract of the present invention can be obtained by extracting fig fruits with hot water and organic solvents. Specifically, after collecting and pulverizing fig fruits, 1 to 50 times the amount of solvent can be added and extracted by immersion, compression, or pulverization at room temperature for 12 hours to 3 months. The extraction solvent may be used for fractional extraction using any one or more solvents selected from the group consisting of purified water, lower alcohols having 1 to 4 carbon atoms, dichloromethane, chloroform, and ethyl acetate. Preferably, fractional extraction can be performed using methanol, ethanol, or ethyl acetate as a solvent.
상기 에키네시아(Echinacea Angustifolia)는 미국 북미 대평원에 서식하는 국화과의 야생 식물로 수세기 동안 감기나 또 다른 바이러스 감염에 의한 질병에 대하여 면역 기능을 증진시키는 전통 식물 약재로 널리 사용되어 왔다. 최근에 에키네시아 추출물은 피부 보호를 위한 화장품 원료로서 응용되어 오고 있다. 상기 에키네시아 추출물은 항산화, 면역증진, 활성산소종 소거, 멜라닌 억제 효과가 있는 것으로 알려져 있다.Echinacea ( Echinacea Angustifolia ) is a wild plant of the Asteraceae family that lives in the Great Plains of North America and has been widely used for centuries as a traditional plant medicine to improve immune function against diseases caused by colds or other viral infections. Recently, Echinacea extract has been applied as a cosmetic raw material for skin protection. The Echinacea extract is known to have antioxidant, immune-enhancing, reactive oxygen species scavenging, and melanin-inhibiting effects.
본 발명에서 아연 혼합물은 징크 피리치온(zinc pyrithione)을 포함할 수 있다. 징크 피리치온은 C10H10N2O2S2Zn의 화학식을 가지는 물질로 (CAS No. 13463-41-7) 항균, 항진균 능력을 가져 보존제로서 사용되며, 특히 비듬균인 말라세지아(Malassezia)의 증식을 억제하는 효과로 인하여 비듬 및 탈모 치료용 모발세정제의 성분으로 사용되어 왔다.In the present invention, the zinc mixture may include zinc pyrithione. Zinc pyrithione is a substance with the chemical formula C 10 H 10 N 2 O 2 S 2 Zn (CAS No. 13463-41-7) and has antibacterial and antifungal properties and is used as a preservative, especially against the dandruff fungus Malassezia ( Due to its effect in suppressing the growth of Malassezia , it has been used as an ingredient in hair cleansers for the treatment of dandruff and hair loss.
상기 징크 피리치온은 물에 대한 용해도가 15ppm수준으로 낮아 화장료나 외용제에서 현탁현상을 보일 수 있다. 이러한 현탁현상을 완화하기 위하여 본 발명의 비건 남성 청결제는 유화안정제로 소듐폴리나프탈렌설포네이트 및/또는 셀룰로오스검을 전체 중량 대비 0.1~5중량부 더 포함하여 징크피리치온 콤플렉스를 형성할 수 있다.The zinc pyrithione has a solubility in water as low as 15ppm, so it may show suspension in cosmetics or external preparations. In order to alleviate this suspension phenomenon, the vegan men's cleanser of the present invention may further include 0.1 to 5 parts by weight of sodium polynaphthalenesulfonate and/or cellulose gum as an emulsion stabilizer based on the total weight to form a zinc pyrithione complex.
본 발명의 비건 남성 청결제는 계면활성제를 포함할 수 있다. 계면활성제는 일예로 라우릴베타인, 소듐코코일이세티오네이트, 소듐코코일글루타메이트, 데실글루코사이드, 포타슘코코일글리시네이트 중 어느 하나 이상의 혼합물을 사용할 수 있으나 이에 제한되는 것은 아니다. 상기 계면활성제는 전체 중량 대비 10~30 중량부를 포함할 수 있다.The vegan male wash of the present invention may include a surfactant. For example, the surfactant may be a mixture of one or more of lauryl betaine, sodium cocoyl isethionate, sodium cocoyl glutamate, decyl glucoside, and potassium cocoyl glycinate, but is not limited thereto. The surfactant may contain 10 to 30 parts by weight based on the total weight.
일 실시예에 있어서, 본 발명의 비건 남성 청결제는 식물성 오일을 포함할 수 있다. 상기 식물성 오일은 티트리잎 오일, 달맞이꽃 오일, 삼씨 오일, 솔잣나무가지 오일, 솔잣나무 잎 오일로 구성되는 군에서 선택되는 어느 하나 이상인 것일 수 있다.In one embodiment, the vegan men's cleanser of the present invention may include vegetable oil. The vegetable oil may be any one or more selected from the group consisting of tea tree leaf oil, evening primrose oil, hemp seed oil, pine pine branch oil, and pine pine leaf oil.
일 실시예에 있어서, 본 발명의 비건 남성 청결제는 산도조절제를 포함할 수 있다. 상기 산도조절제는 코코넛애씨드, 시트릭애씨드와 같은 유기산일 수 있다.In one embodiment, the vegan male wash of the present invention may include an acidity regulator. The acidity regulator may be an organic acid such as coconut acid or citric acid.
일 실시예에 있어서, 본 발명의 비건 남성 청결제는 알지닌을 포함할 수 있다. 상기 알지닌은 아미노산의 한 종류로, 피부의 수분을 잡아주는 보습효과와 특유의 향을 지녀 화장품에 널리 사용되고 있다. 또한 강염기성을 지니고 있어 화장품의 산도조절제로도 사용되고 있다.In one embodiment, the vegan men's wash of the present invention may include arginine. The arginine is a type of amino acid and is widely used in cosmetics because it has a moisturizing effect that retains moisture in the skin and a unique scent. It also has strong alkaline properties, so it is also used as an acidity regulator in cosmetics.
또한 본 발명의 비건 남성 청결제는 리포좀 구조체를 포함할 수 있다. 상기 리포좀은 일반적으로는 피부의 세포막을 투과하기 힘든 극성물질이나 고분자물질을 생체막과 유사한 성분의 지질막으로 둘러싸 세포막의 투과를 돕고, 유효성분의 체내 흡수를 촉진시키는 역할을 한다.Additionally, the vegan men's cleanser of the present invention may include a liposome structure. The liposome generally surrounds polar substances or polymer substances that are difficult to penetrate the cell membrane of the skin with a lipid membrane made of components similar to biological membranes, thereby helping the penetration of the cell membrane and promoting the absorption of active ingredients into the body.
상기 리포좀을 형성하기 위하여 본 발명은 레시틴을 1~8 중량부, 카프릴릴글라이콜 1~5 중량부, 카프릴릭/카프릭 트라이글리세라이드 1~5 중량부, 글리세린 3~10 중량부를 더 포함할 수 있다. 레시틴은 양수성을 가지는 인지질의 일 부류로 동, 식물에 광범위하게 함유되어 있으며, 콩, 달걀, 젖, 종자유 등에서 쉽게 구할 수 있다. 피담지물질과 레시틴, 계면활성제, 오일 성분을 혼합하여 통상의 고압유화장치를 이용한 방법을 이용하여 피담지물질을 리포좀 구조체로 담지시킬 수 있다.In order to form the liposome, the present invention further adds 1 to 8 parts by weight of lecithin, 1 to 5 parts by weight of caprylyl glycol, 1 to 5 parts by weight of caprylic/capric triglyceride, and 3 to 10 parts by weight of glycerin. It can be included. Lecithin is a type of amniotic phospholipid and is widely found in animals and plants, and can be easily obtained from soybeans, eggs, milk, and seed oil. The supported material can be mixed into a liposome structure by mixing the supported material with lecithin, surfactant, and oil components and using a method using a typical high-pressure emulsification device.
한편, 본 발명의 비건 남성 청결제는 황색포도상구균(Staphylococcus aureus), 대장균(Escherichia coli) 및 칸디다균(Candida albicans)에 대해 생장 억제효과를 가진다.Meanwhile, the vegan men's cleanser of the present invention has a growth inhibitory effect on Staphylococcus aureus , Escherichia coli , and Candida albicans .
상기 칸디다균은 인체의 피부, 구강, 소화관, 음부 등에 정상적으로 상주하며 일반적으로는 유해하지 않은 진균이다. 그러나 일시적으로 체내의 면역능력이 약화되면 점막과 피부의 습한 부위에서 과다증식하여 아구창, 구인두나 식도의 염증, 외음부염, 질염, 손발톱 주위염 등의 칸디다증을 유발하게 된다. 특히 여성의 외음부염과 질염의 70%가 칸디다증과 같은 세균성 염증에 의한 것으로, 외음부의 소양감, 따가움, 질 통증, 성교 시의 통증 및 흰 색의 덩어리진 질 분비물 등의 증상이 나타난다. 남성의 성기 또한 감염되었을 경우, 귀두의 가려움, 발진, 수포, 악취, 배뇨 통증 및 드물게 요도염을 나타낼 수 있다. 또한 포경을 하지 않은 남성의 포피와 귀두 사이에 스메그마(smegma)가 증가하고 악취를 유발하게 된다.The Candida bacteria are fungi that normally reside on the skin, oral cavity, digestive tract, genital area, etc. of the human body and are generally not harmful. However, if the body's immune system is temporarily weakened, it can overproliferate in moist areas of the mucous membrane and skin, causing candidiasis such as thrush, inflammation of the oropharynx or esophagus, vulvovaginitis, vaginitis, and paronychia. In particular, 70% of vulvovaginitis and vaginitis in women are caused by bacterial inflammation such as candidiasis, and symptoms include vulvar itching, stinging, vaginal pain, pain during intercourse, and white lumpy vaginal discharge. If the male genitals are also infected, itching of the glans penis, rash, blisters, foul odor, painful urination, and rarely urethritis may occur. Additionally, smegma increases between the foreskin and glans of uncircumcised men, causing a foul odor.
본 발명의 실시예에서 상기 칸디다증의 원인이 되는 칸디다균과, 각종 피부염 및 알러지 반응을 유발할 수 있는 대장균 및 황색포도상구균을 효과적으로 억제할 수 있음을 확인할 수 있었다.In the examples of the present invention, it was confirmed that Candida, which causes candidiasis, and Escherichia coli and Staphylococcus aureus, which can cause various dermatitis and allergic reactions, can be effectively suppressed.
본 발명의 비건 남성 청결제는 동물성 원료를 사용하지 않고, 식물 유래성 원료 및 식물 추출물을 사용하여 친환경적이며, 비건(vegan) 주의자들의 수요를 총족시킬 수 있다.The vegan men's cleanser of the present invention does not use animal raw materials, but uses plant-derived raw materials and plant extracts, so it is environmentally friendly and can meet the needs of vegans.
본 발명의 비건 남성 청결제는 비듬균 억제 두피 개선제, 무좀 증세 완화용 족부 세정제, 겨드랑이 암내 제거제 등과 같은 인체 상피 균총에 의한 피부 질환 및 소취를 위한 화장료 또는 외용제 조성물로 응용가능하나 이에 국한하지 않는다.The vegan men's cleanser of the present invention can be applied as a cosmetic or external composition for deodorization and skin diseases caused by human epithelial flora, such as a scalp improver to inhibit dandruff, a foot wash for alleviating athlete's foot symptoms, and an armpit cancer remover, but is not limited thereto.
본 발명에 의하면 칸디다증을 예방하는 천연물 유래 항균 항진균 성분의 국부 세정제를 제공하여, 생식기 위생 상태 개선에 도움을 주는 효과가 있다.According to the present invention, a local cleanser containing antibacterial and antifungal ingredients derived from natural products to prevent candidiasis is provided, which has the effect of helping to improve genital hygiene.
또한, 천연 항생물질을 포함하여 피부 자극성을 줄이고 악취를 감소시켜 성생활 만족도를 높이는 효과가 있다.In addition, it contains natural antibiotics, which has the effect of reducing skin irritation and bad odor, thereby increasing satisfaction with sexual life.
또한, 동물성 원료를 사용하지 않아 비건(vegan) 주의자들의 수요를 충족시킬 수 있는 효과가 있다.In addition, since it does not use animal raw materials, it has the effect of meeting the demand of vegans.
이하, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 본 발명의 실시예에 대하여 상세히 설명한다. 그러나 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되지 않는다. Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily practice it. However, the present invention may be implemented in many different forms and is not limited to the embodiments described herein.
제조예 1. 무화과 효소 추출물 수득과정Preparation Example 1. Process for obtaining fig enzyme extract
전남 영암군 일대에서 재배되고 있는 봉래시 품종의 무화과 열매를 채취하여 분쇄한 후, 10배 중량의 에탄올 용매를 가하여 상온에서 24시간동안 침적법으로 추출하고 부흐너 깔때기(Buchner funnel)로 흡인 여과하여, 추출액을 혼합하여 50에서 감압농축기를 사용하여 에탄올을 제거하여 무화과 효소 추출물을 얻었다. 상기 추출 및 농축과정은 3회 반복 실시하였다.Fig fruits of the Bongraesi variety grown in Yeongam-gun, Jeollanam-do were collected and crushed, then 10 times the weight of ethanol solvent was added, extracted by immersion at room temperature for 24 hours, and suction filtered using a Buchner funnel to produce the extract. Mix 50 Ethanol was removed using a vacuum concentrator to obtain a fig enzyme extract. The extraction and concentration process was repeated three times.
제조예 2 내지 5. 무화과 효소 분획물 수득Preparation Examples 2 to 5. Obtaining fig enzyme fraction
상기 제조예 1에서 수득한 무화과 효소 추출물을 5배 중량의 n-헥세인(hexane) 용매로 3회 추출 후 감압농축하여 무화과 효소 헥세인 분획물을 수득하였다. 이후 순차적으로 클로로폼(chloroform), 에틸 아세테이트(ethyl acetate), n-뷰탄올(butanol) 용매로 동일하게 추출하여 각각의 분획물을 수득하였다.The fig enzyme extract obtained in Preparation Example 1 was extracted three times with 5 times the weight of n-hexane solvent and then concentrated under reduced pressure to obtain a fig enzyme hexane fraction. Afterwards, each fraction was obtained by sequentially extracting the same with chloroform, ethyl acetate, and n-butanol solvents.
제조예 6. 에키네시아 추출물 제조Preparation Example 6. Preparation of Echinacea extract
에키네시아의 꽃, 잎, 줄기, 뿌리를 건조 분쇄하여 에키네시아 건조 분말을 수득하였다. 수득한 에키네시아 건조 분말을 20배 중량의 물을 가한 후 4시간 동안 끓여 열수 추출한 뒤 여과하여 여과액을 동결 건조하여 열수 추출물을 수득하였다. 이후 열수 추출물을 20배 중량의 75% 에탄올에 24시간 침적하고 침출액을 감압농축하여 에키네시아 추출물을 제조하였다.Echinacea dried powder was obtained by drying and grinding the flowers, leaves, stems, and roots of Echinacea. The obtained dried Echinacea powder was added with 20 times the weight of water, boiled for 4 hours, extracted with hot water, filtered, and the filtrate was freeze-dried to obtain a hot water extract. Afterwards, the hot water extract was immersed in 20 times the weight of 75% ethanol for 24 hours and the leachate was concentrated under reduced pressure to prepare an Echinacea extract.
<실시예 1> <Example 1>
전체 조성물 총 중량 대비 상기 제조예 1의 무화과 효소 추출물 2 중량부, 제조예 6의 에키네시아 추출물 1.5 중량부, 징크피리치온 0.3 중량부, 소듐폴리나프탈렌설포네이트 3 중량부 및 나머지 중량부의 정제수를 혼합하여 조성물을 제조하였다.Based on the total weight of the entire composition, 2 parts by weight of the fig enzyme extract of Preparation Example 1, 1.5 parts by weight of the Echinacea extract of Preparation Example 6, 0.3 parts by weight of zinc pyrithione, 3 parts by weight of sodium polynaphthalenesulfonate, and the remaining parts by weight of purified water A composition was prepared by mixing.
<실시예 2 내지 5><Examples 2 to 5>
상기 실시예 1의 조성물에서 무화과 효소 추출물을 제조예 2의 무화과 효소 헥세인 분획물로 대체한 것을 제외하고는 동일한 방법으로 제조하여 실시예 2의 조성물을 획득하였다. 유사하게 실시예 1의 조성물에서 무화과 효소 추출물을 각각 제조예 3 내지 5의 클로로폼, 에틸 아세테이트, 뷰탄올 분획물로 대체하여 각각 실시예 3 내지 5의 조성물을 제조하였다.The composition of Example 2 was obtained by preparing it in the same manner, except that the fig enzyme extract in the composition of Example 1 was replaced with the fig enzyme hexane fraction of Preparation Example 2. Similarly, the compositions of Examples 3 to 5 were prepared by replacing the fig enzyme extract in the composition of Example 1 with the chloroform, ethyl acetate, and butanol fractions of Preparation Examples 3 to 5, respectively.
<실시예 6><Example 6>
전체 조성물 총 중량 대비 상기 제조예 4의 무화과 효소 에틸 아세테이트 분획물 2 중량부, 제조예 6의 에키네시아 추출물 1.5 중량부, 징크피리치온 0.3 중량부, 소듐폴리나프탈렌설포네이트 3 중량부, 레시틴 6 중량부, 카프릴릴글라이콜 3 중량부, 카프릴릭/카프릭 트라이글리세라이드 3 중량부, 글리세린 5 중량부를 혼합하고, 압력 1200 bar, 유속 500m/s의 조건하에서 고압유화장치(Microfludizer)에 5회 통과시켜, 안정화시킨 리포좀을 얻었다.Based on the total weight of the entire composition, 2 parts by weight of the fig enzyme ethyl acetate fraction of Preparation Example 4, 1.5 parts by weight of the Echinacea extract of Preparation Example 6, 0.3 parts by weight of zinc pyrithione, 3 parts by weight of sodium polynaphthalenesulfonate, and 6 parts by weight of lecithin. 3 parts by weight of caprylyl glycol, 3 parts by weight of caprylic/capric triglyceride, and 5 parts by weight of glycerin were mixed, and 5 parts by weight were placed in a high-pressure emulsifier (Microfludizer) under the conditions of a pressure of 1200 bar and a flow speed of 500 m/s. After passage, stabilized liposomes were obtained.
<비교예 1> <Comparative Example 1>
상기 실시예 6과 동일한 조성비의 조성물을 제조하되, 고압유화장치를 이용하지 않고 단순 혼합하여 조성물을 제조하였다.A composition having the same composition ratio as in Example 6 was prepared by simple mixing without using a high-pressure emulsifier.
<실시예 7> <Example 7>
상기 실시예 6의 조성물에 계면활성제 20 중량부, 알지닌 0.5 중량부, 산도조절제 0.4 중량부, 및 나머지 중량부의 정제수를 혼합하여 청결제 조성물을 제조하였다.A cleaning composition was prepared by mixing the composition of Example 6 with 20 parts by weight of surfactant, 0.5 parts by weight of arginine, 0.4 parts by weight of an acidity regulator, and the remaining parts by weight of purified water.
상기 계면활성제는 라우릴베타인, 소듐코코일이세티오네이트, 소듐코코일글루타메이트, 데실글루코사이드, 포타슘코코일글리시네이트를 동일한 부피로 혼합한 것을 사용하였다.The surfactant used was a mixture of lauryl betaine, sodium cocoyl isethionate, sodium cocoyl glutamate, decyl glucoside, and potassium cocoyl glycinate in equal volumes.
상기 산도조절제는 코코넛애씨드와 시트릭애씨드를 동일한 중량으로 혼합한 것을 사용하였다. 제조된 청결제 조성물의 산도는 pH 7.4의 중성을 나타내었다.The acidity regulator used was a mixture of coconut acid and citric acid in equal weight. The acidity of the prepared cleaning composition was neutral at pH 7.4.
<실시예 8><Example 8>
상기 실시예 7의 조성물에 식물성 오일 8 중량부를 더 첨가하여 청결제 조성물을 제조하였다. 상기 식물성 오일은 티트리잎 오일, 달맞이꽃 오일, 삼씨 오일, 솔잣나무가지 오일, 솔잣나무 잎 오일을 2:2:2:1:1의 중량비로 혼합한 것을 사용하였다.A cleaning composition was prepared by adding 8 parts by weight of vegetable oil to the composition of Example 7. The vegetable oil used was a mixture of tea tree leaf oil, evening primrose oil, hemp seed oil, pine pine branch oil, and pine pine leaf oil in a weight ratio of 2:2:2:1:1.
<비교예 2><Comparative Example 2>
계면활성제 20 중량부, 알지닌 0.5 중량부, 산도조절제 0.4 중량부, 및 나머지 중량부의 정제수를 혼합하여 청결제 조성물을 제조하였다. 계면활성제와 산도조절제는 상기 실시예 7과 같은 구성으로 제조하였다.A cleaning composition was prepared by mixing 20 parts by weight of a surfactant, 0.5 parts by weight of arginine, 0.4 parts by weight of an acidity regulator, and the remaining parts by weight of purified water. The surfactant and acidity regulator were prepared in the same configuration as Example 7 above.
<비교예 3><Comparative Example 3>
상기 비교예 2의 조성물에 식물성 오일 8 중량부를 더 첨가하여 청결제 조성물을 제조하였다. 식물성 오일은 상기 실시예 8과 같은 구성으로 제조하였다.A cleaning composition was prepared by adding 8 parts by weight of vegetable oil to the composition of Comparative Example 2. Vegetable oil was prepared in the same manner as Example 8 above.
시험예 1. 항균 능력 평가Test Example 1. Antibacterial ability evaluation
본 발명의 청결제의 항균 능력을 디스크 확산 검사법으로 시험하였다. 시험 균주는 그람 양성균인 황색포도상구균(Staphylococcus aureus) 및 그람 음성균인 대장균(Escherichia coli)을 선택하였다. 각 균주를 LB 액체 배지(Luria-Berani broth)에 접종하여 각각 37℃에서 24시간 배양하였다. 배양된 배양액은 흡광도를 측정하여 0.5 McFarland 기준으로 희석하여 준비되었다.The antibacterial ability of the cleaning agent of the present invention was tested using the disk diffusion test. Staphylococcus aureus , a gram-positive bacterium, and Escherichia coli, a gram-negative bacterium, were selected as test strains. Each strain was inoculated into LB liquid medium (Luria-Berani broth) and cultured at 37°C for 24 hours. The cultured medium was prepared by measuring the absorbance and diluting it to 0.5 McFarland standard.
한편, Muller Hilton(MH) agar를 멸균 페트리 디시에 4mm 두께로 붓고 식혀 고형화시킨 고체 배지를 준비하였다. MH 고체 배지에 전술한 배양액 100㎕를 고르게 도말하였다. 이후 도말한 MH 배지에 페이퍼 디스크를 얹고 실시예 1 내지 4의 무화과 분획물 50㎕를 흡착시킨 다음 37℃에서 24시간 배양하여 억제대(zone of inhibition)의 직경을 측정하였다.Meanwhile, a solid medium was prepared by pouring Muller Hilton (MH) agar into a sterile Petri dish to a thickness of 4 mm and cooling and solidifying it. 100 ㎕ of the above-mentioned culture medium was evenly spread on MH solid medium. Afterwards, a paper disc was placed on the smeared MH medium, 50㎕ of the fig fractions of Examples 1 to 4 were adsorbed, and the culture was incubated at 37°C for 24 hours to measure the diameter of the zone of inhibition.
시험 결과, 상기 표 1과 같이 실시예 4의 무화과 에틸 아세테이트 분획물을 포함한 조성물이 황색포도상구균 배지에서 17mm의 억제대를 형성하였고, 대장균 배지에서 15mm의 억제대를 형성하여 항균 능력이 가장 우수함을 확인할 수 있었다.As a result of the test, as shown in Table 1 above, the composition containing the fig ethyl acetate fraction of Example 4 formed an inhibition zone of 17 mm in the Staphylococcus aureus medium and an inhibition zone of 15 mm in the E. coli medium, confirming that it had the best antibacterial ability. .
시험예 2. 항진균 능력 평가Test Example 2. Evaluation of antifungal ability
본 발명의 청결제의 항균 능력을 디스크 확산 검사법으로 시험하였다. 시험 진균은 칸디다균(Candida albicans)을 선택하였다. 칸디다균을 Potato Dextrose Broth (PDB)에 접종하여 30℃에서 3일간 배양하였다. 배양된 배양액은 흡광도를 측정하여 0.5 McFarland 기준으로 희석하여 준비되었다.The antibacterial ability of the cleaning agent of the present invention was tested using the disk diffusion test. Candida albicans was selected as the test fungus. Candida bacteria were inoculated into Potato Dextrose Broth (PDB) and cultured at 30°C for 3 days. The cultured medium was prepared by measuring the absorbance and diluting it to 0.5 McFarland standard.
한편, Potato Dextrose Agar (PDA)를 멸균 페트리 디시에 4mm 두께로 붓고 식혀 고형화시킨 고체 배지를 준비하였다. PDA 고체 배지에 전술한 배양액 100㎕를 고르게 도말하였다. 이후 도말한 PDA 배지에 페이퍼 디스크를 얹고 실시예 1 내지 4의 무화과 분획물 50㎕를 흡착시킨 다음 30℃에서 48시간 배양하여 억제대(zone of inhibition)의 직경을 측정하였다.Meanwhile, a solid medium was prepared by pouring Potato Dextrose Agar (PDA) into a sterile Petri dish to a thickness of 4 mm and cooling and solidifying it. 100 ㎕ of the above-mentioned culture medium was evenly spread on PDA solid medium. Afterwards, a paper disk was placed on the smeared PDA medium, 50㎕ of the fig fractions of Examples 1 to 4 were adsorbed, and the culture was incubated at 30°C for 48 hours to measure the diameter of the zone of inhibition.
시험 결과, 상기 표 2와 같이 실시예 4의 무화과 에틸 아세테이트 분획물을 포함한 조성물이 12mm의 억제대를 형성하여 항진균 능력이 가장 우수함을 확인할 수 있었다.As a result of the test, as shown in Table 2 above, it was confirmed that the composition containing the fig ethyl acetate fraction of Example 4 had the best antifungal ability by forming an inhibition zone of 12 mm.
시험예 3. 경피 흡수 능력 평가Test Example 3. Evaluation of transdermal absorption capacity
상기 실시예 4, 실시예 6, 비교예 1에 대하여 프란츠 디퓨젼 셀(Franz diffusion cell, 유효면적: 0.64㎠, 수용칸의 부피: 5ml)을 사용하여 싱크 조건(sink condition)하에서 피부 투과 시험을 실시하였다. 수용상은 pH 7.4의 인산 완충 식염수(Phosphate buffered saline, PBS)를 사용하였다.For Example 4, Example 6, and Comparative Example 1, a skin permeation test was conducted under sink conditions using a Franz diffusion cell (effective area: 0.64 cm2, volume of storage compartment: 5 ml). It was carried out. Phosphate buffered saline (PBS) at pH 7.4 was used as the aqueous phase.
준비된 인체 피부의 표피층(1.5 cm x 1.5 cm)을 수용칸(receptor chamber) 위에 각질층(stratum corneum)이 위로 위치하도록 하여 위치시키고, 공여칸(donor chamber)을 덮어 클램프로 고정시킨 후 수용상을 프란츠 디퓨젼 셀에 채우고 32±1로 유지시켰다. 상기 제조된 실시예 4, 실시예 6, 비교예 1을 공여부위에 부착하여 투과 실험을 실시하였다. 투과 실험 실시 후 30분, 1시간, 2시간, 4시간, 6시간, 24시간 경과시 수용상 5ml을 채취 및 분석하고, 새로운 인산 완충 식염수로 보충하였다. The prepared epidermal layer of human skin (1.5 cm Fill the diffusion cell and fill it with 32±1 was maintained. A permeation experiment was performed by attaching the prepared Examples 4, 6, and Comparative Example 1 to the donor site. At 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 24 hours after the permeation experiment, 5 ml of the aqueous phase was collected and analyzed, and supplemented with fresh phosphate-buffered saline solution.
인공피부는 한스바이오메드 사에서 구매하여 사용하였고, 구매 후 -20에서 보관하였으며, 사용 시 인산 완충 식염수에 30분간 세척 및 수화시켜 사용하였다.Artificial skin was purchased and used from Hans Biomed, and after purchase, -20% It was stored in , and when used, it was washed and hydrated in phosphate buffered saline solution for 30 minutes.
채취된 인산 완충 식염수는 고성능 액체 크로마토그래피(HPLC, High-performance liquid chromatography)를 통해 분석하여 피부 투과율을 하기 표 3에 정리하였다.The collected phosphate-buffered saline solution was analyzed through high-performance liquid chromatography (HPLC), and the skin penetration rate is summarized in Table 3 below.
상기 표 3을 참조하면, 실시예 4의 유효 성분만을 혼합한 조성물은 피부 투과율이 높지 않은 결과를 나타내었다. 한편, 비교예 1의 레시틴 포함 조성물에서도 피부 투과율은 실시예 4와 유사하게 피부 투과율이 높지 않았다. 반면, 실시예 6의 리포좀 형성한 조성물은 유의미하게 높은 피부 투과율을 보여 실시에 6의 조성물이 우수한 경피 흡수 효과를 보인다는 것을 확인할 수 있었다.Referring to Table 3, the composition containing only the active ingredients of Example 4 did not have a high skin permeability. Meanwhile, the skin permeability of the composition containing lecithin of Comparative Example 1 was not high, similar to Example 4. On the other hand, the liposome-formed composition of Example 6 showed a significantly higher skin permeability, confirming that the composition of Example 6 showed an excellent transdermal absorption effect.
시험예 4. 관능평가Test Example 4. Sensory evaluation
20대 ~ 40대의 남성 30명을 대상으로 실시예 7 내지 8, 비교예 2 내지 3의 청결제 조성물을 각각 매일 1회, 2주간 사용하게 하여 관능성을 평가하였다. 이때 청결제는 제공된 용기로 1회 펌프(2mg)하여 남성의 Y존을 세정 후 최소 3분간 유지한 후 씻어내도록 하여 청결제의 구성성분이 충분히 흡수될 수 있도록 지시하였다. 평가 항목은 자극성(따끔거리거나 홍반, 발진이 일어난 정도), 소취능(본인 혹은 파트너가 느낀 만족도), 건조함(각질이 일어난 정도), 사용감으로 분류하였고, 5점 척도법을 사용하여 가장 만족할 경우 5점, 가장 불만족할 경우 1점을 부여하도록 하여 평가하여 하기 표 4에 정리하였다.Sensory properties were evaluated by having 30 men in their 20s to 40s use the cleaning compositions of Examples 7 to 8 and Comparative Examples 2 to 3 once a day for 2 weeks, respectively. At this time, instructions were given to pump the cleanser once (2 mg) into the provided container, clean the man's Y zone, hold it for at least 3 minutes, and then rinse it off so that the ingredients of the cleanser could be sufficiently absorbed. The evaluation items were categorized into irritation (stinging, erythema, or rash), deodorizing ability (satisfaction felt by the user or partner), dryness (degree of exfoliation), and feeling of use. A 5-point scale was used to determine the most satisfactory condition. The evaluation was given 5 points, and 1 point for the most dissatisfied, and is summarized in Table 4 below.
상기 표 4의 결과를 참조하면, 실시예 8의 청결제 조성물이 피부를 자극하거나 건성화하는 부작용은 덜하면서 높은 소취능력과 사용감을 가져 전반적으로 가장 높은 만족도를 얻음을 확인할 수 있다.Referring to the results in Table 4 above, it can be seen that the cleaning composition of Example 8 achieved the highest overall satisfaction level by having a high deodorizing ability and feeling of use while having less side effects such as irritating or drying the skin.
Claims (4)
무화과 효소 추출물 0.1~3 중량부, 에키네시아 추출물 0.1~2 중량부, 징크피리치온 0.05~0.5 중량부, 소듐폴리나프탈렌설포네이트 0.5~5 중량부를 유효 성분으로 하고,
계면활성제 10~30 중량부, 식물성 오일 5~10 중량부, 산도조절제 0.1~3 중량부 및 나머지 중량부의 정제수를 더 포함하는, 칸디다증을 예방하는 천연물 유래 항균 항진균 성분의 국부 세정제.Compared to the total weight of topical cleansers derived from natural products
The active ingredients include 0.1 to 3 parts by weight of fig enzyme extract, 0.1 to 2 parts by weight of Echinacea extract, 0.05 to 0.5 parts by weight of zinc pyrithione, and 0.5 to 5 parts by weight of sodium polynaphthalenesulfonate,
A local cleanser containing antibacterial and antifungal ingredients derived from natural products to prevent candidiasis, further comprising 10 to 30 parts by weight of a surfactant, 5 to 10 parts by weight of vegetable oil, 0.1 to 3 parts by weight of an acidity regulator, and the remaining parts by weight of purified water.
상기 무화과 효소 추출물은, 무화과 열매에서 정제수, 탄소수 1 내지 4의 저급 알코올, 다이클로로메테인, 클로로포름 및 에틸 아세테이트로 이루어지는 군에서 선택되는 어느 하나 이상의 용매로 분획 추출한 것인 천연물 유래 국부 세정제.According to paragraph 1,
The fig enzyme extract is a natural product-derived topical cleanser that is fractionated from fig fruit with one or more solvents selected from the group consisting of purified water, lower alcohols having 1 to 4 carbon atoms, dichloromethane, chloroform, and ethyl acetate.
상기 식물성 오일은, 티트리잎 오일, 달맞이꽃 오일, 삼씨 오일, 솔잣나무가지 오일, 솔잣나무 잎 오일로 구성되는 군에서 선택되는 어느 하나 이상인 것인 천연물 유래 국부 세정제.According to paragraph 1,
The vegetable oil is a natural product-derived topical cleanser, wherein the vegetable oil is at least one selected from the group consisting of tea tree leaf oil, evening primrose oil, hemp seed oil, pine pine branch oil, and pine pine leaf oil.
상기 천연물 유래 국부 세정제는 황색포도상구균(Staphylococcus aureus), 대장균(Escherichia coli) 및 칸디다균(Candida albicans)에 대해 생장 억제능력을 가지는 것인 천연물 유래 국부 세정제.According to paragraph 1,
The natural product-derived topical cleanser is a natural product-derived topical cleanser that has growth inhibition ability against Staphylococcus aureus , Escherichia coli, and Candida albicans .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220084216A KR20240007391A (en) | 2022-07-08 | 2022-07-08 | A local cleanser with antibacterial and antifungal ingredients derived from natural products to prevent candidiasis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220084216A KR20240007391A (en) | 2022-07-08 | 2022-07-08 | A local cleanser with antibacterial and antifungal ingredients derived from natural products to prevent candidiasis |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20240007391A true KR20240007391A (en) | 2024-01-16 |
Family
ID=89719627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220084216A KR20240007391A (en) | 2022-07-08 | 2022-07-08 | A local cleanser with antibacterial and antifungal ingredients derived from natural products to prevent candidiasis |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20240007391A (en) |
-
2022
- 2022-07-08 KR KR1020220084216A patent/KR20240007391A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102518446B1 (en) | Natural Ingredient-Based Men's Cleaner | |
JP6626902B2 (en) | Antimicrobial herbal composition, method for producing and using the same | |
JP2008534675A (en) | Antibacterial composition containing natural extract, nanosilver, and natural essential oil | |
KR101532005B1 (en) | Natural preservative comprising citrus junos seed extract and manufacturing method thereof | |
KR102103021B1 (en) | Antiatopyic and antivaginitis tissues containing retinispora extracts and a process for the preparation thereof | |
KR20160015718A (en) | Feminine cleanser composition comprising Portulaca oleracea extract and Phytoncide | |
CN112048402B (en) | Antibacterial, stain-removing and peculiar smell-removing underwear soap and preparation method thereof | |
KR102133101B1 (en) | A Feminine cleanser composition comprising imperata cylindrica leaf and artemisia princeps | |
KR102296688B1 (en) | Composition for maintaining vaginal health derived from natural products | |
KR101930264B1 (en) | Cosmetic composition for inhibiting secretion of sebum and for improving acne symptoms containing natural complex extract | |
KR101104898B1 (en) | Skin detergent composition for anti-bacterial by using oriental herb extract | |
KR100903827B1 (en) | The hand-made traditional oriental soap and the manufacture method | |
KR102049278B1 (en) | A antibacterial composition containing the extracts of silk tree bark and the feminine cleanser composition comprising the same | |
KR102488821B1 (en) | Manufacturing method of tee-tree extract and antimicrobial compositon comprising the same | |
KR102373422B1 (en) | Composition for vaginal cleaning including functional peptides | |
CN114306526B (en) | Compound broadleaf holly leaf traditional Chinese medicine extract and application thereof in preparing shower gel or hand sanitizer | |
KR101427462B1 (en) | Composite Natural Antiseptics From Forsythia suspensa Vahl, Leonurus sibiricus L., Crataegi fructus and Akebia quinata Decaisne, Cosmetic Compositions Containing Them | |
CN110200870A (en) | A kind of reparation moisture retention water containing solanum lyratum and Flos Hibisci extract | |
KR20240007391A (en) | A local cleanser with antibacterial and antifungal ingredients derived from natural products to prevent candidiasis | |
KR20240007393A (en) | Eco-friendly cleaning composition for reducing male genital odor | |
KR102448555B1 (en) | Antimicrobial and Antifungal Cosmetic Composition Containing Complex Extract of Chamaecyparis obtusa, Rosa rugosa, and Melissa officinalis as Active Ingredient | |
KR102269881B1 (en) | Composition with antimicrobial or antifungal activity comprising dryopteris crassirhizoma nakai extract, salvia miltiorrhiza bunge extract and scutellaria baicalensis extract and method for preaparing the same | |
KR102172448B1 (en) | A antibacterial composition containing the defatted Camellia's seed extract and the feminine cleanser composition comprising the same | |
KR101598194B1 (en) | Multifunctional deodorant cosmetic composition for hair and body | |
KR101432996B1 (en) | CLEANSING COMPOSITION COMPRISING NATURAL COMPOUNDS EXTRACT OF Oenanthe javanica DC, Artemisia capillaris and Artemisiae capillaris Flos COMPLEX FOR LADIES, ITS METHOD TO USE AND PROCESS THEREOF |